This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — Open Labs, Open Minds (B)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M110-EStrategyThis case is a supplement to GSK’s Andrew Witty (A).Starting at €5.74
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — The Pharmaceutical Patent Pool (A)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M109-EStrategyIn February 2009, Andrew Witty, CEO of GlaxoSmithKline (GSK), reflected on his vision for big pharma as a catalyst for change which focussed on two key issues: 1) promoting innovation for the products that treat or prevent neglected tropical diseases and 2) improving access to medicines in the world’s poorest countries. He had announced the creation of the Pharmaceutical Patent Pool and wondered if it was the right strategy to deliver results on ...Starting at €8.20
-
Thomas Cook Group: Do Insiders or Outsiders Make Better CEOs?
Wiboon Kittilaksanawong; Kinley BidhaCase IVEY-W25320-EStrategyIn September 2019, Thomas Cook Group Plc (Thomas Cook), an iconic 178-year-old travel company based in London, United Kingdom, ceased its business after a failed negotiation to fund its huge debt of £1.7 billion (US$2.25 billion). The collapse caused abouStarting at €8.20